Itch and skin rash from chocolate during fluoxetine and sertraline treatment: Case report

BACKGROUND: The skin contains a system for producing serotonin as well as serotonin receptors. Serotonin can also cause pruritus when injected into the skin. SSRI-drugs increase serotonin concentrations and are known to have pruritus and other dermal side effects. CASE PRESENTATION: A 46-year-old man consulted his doctor due to symptoms of depression. He did not suffer from any allergy but drinking red wine caused vasomotor rhinitis. Antidepressive treatment with fluoxetine 20 mg daily was initiated which was successful. After three weeks of treatment an itching rash appeared. An adverse drug reaction (ADR) induced by fluoxetine was suspected and fluoxetine treatment was discontinued. The symptoms disappeared with clemastine and betametasone treatment. Since the depressive symptoms returned sertraline medication was initiated. After approximately two weeks of sertraline treatment he noted an intense itching sensation in his scalp after eating a piece of chocolate cake. The itch spread to the arms, abdomen and legs and the patient treated himself with clemastine and the itch disappeared. He now realised that he had eaten a chocolate cake before this episode and remembered that before the first episode he had had a chocolate mousse dessert. He had never had any reaction from eating chocolate before and therefore reported this observation to his doctor. CONCLUSIONS: This case report suggests that there may be individuals that are very sensitive to increases in serotonin concentrations. Dermal side reactions to SSRI-drugs in these patients may be due to high activity in the serotonergic system at the dermal and epidermo-dermal junctional area rather than a hypersensitivity to the drug molecule itself

Hot gas in Mach cones around Virgo Cluster spiral galaxies

The detailed comparison between observations and simulations of ram pressure stripped spiral galaxies in the Virgo cluster has led to a three dimensional view of the galaxy orbits within the hot intracluster medium. The 3D velocities and Mach numbers derived from simulations can be used to derive simple Mach cone geometries for Virgo spiral galaxies. We search for indications of hot gas within Mach cones in X-ray observations of selected Virgo Cluster spiral galaxies (NGC 4569, NGC 4388, and NGC 4501). We find extraplanar diffuse X-ray emission in all galaxies. Based on the 3D velocity vectors from dynamical modelling a simple Mach cone is fitted to the triangular shape of NGC 4569's diffuse X-ray emission. Assuming that all extraplanar diffuse X-ray emission has to be located inside the Mach cone, we also fit Mach cones to NGC 4388's and NGC 4501's extraplanar X-ray emission. For NGC 4569 it is hard to reconcile the derived Mach cone opening angle with a Mach number based on the sound speed alone. Instead, a Mach number involving the Alfv\'enic speed seems to be more appropriate, yielding a magnetic field strength of $\sim 3$-6 $\mu$G for a intracluster medium density of $n \sim 10^{-4}$ cm$^{-3}$. Whereas the temperature of the hot component of NGC 4569's X-ray halo (0.5 keV) is at the high end but typical for a galactic outflow, the temperature of the hot gas tails of NGC 4388 and NGC 4501 are significantly hotter (0.7-0.9 keV). In NGC 4569 we find direct evidence for a Mach cone which is filled with hot gas from a galactic superwind. We suggest that the high gas temperatures in the X-ray tails of NGC 4388 and NGC 4501 are due to the mixing of the stripped ISM into the hot intracluster medium of the Virgo cluster.Comment: 11 pages, 10 figures, 5 tables. Accepted for publication in Astronomy and Astrophysic

The optical/X-ray connection: ICM iron content and galaxy optical luminosity in 20 galaxy clusters

X-ray observations of galaxy clusters have shown that the intra-cluster gas has iron abundances of about one third of the solar value. These observations also show that part (if not all) of the intra-cluster gas metals were produced within the member galaxies. We present a systematic analysis of 20 galaxy clusters to explore the connection between the iron mass and the total luminosity of early-type and late-type galaxies, and of the brightest cluster galaxies (BCGs). From our results, the intra-cluster medium (ICM) iron mass seems to correlate better with the luminosity of the BCGs than with that of the red and blue galaxy populations. As the BCGs cannot produce alone the observed amount of iron, we suggest that ram-pressure plus tidal stripping act together to enhance, at the same time, the BCG luminosities and the iron mass in the ICM. Through the analysis of the iron yield, we have also estimated that SN Ia are responsible for more than 50% of the total iron in the ICM. This result corroborates the fact that ram-pressure contributes to the gas removal from galaxies to the inta-cluster medium, being very efficient for clusters in the temperature range 2 < kT (keV)< 10Comment: Accepted for publication in MNRAS (11 pg, 9 figures and 3 tables

The GALFA-HI Compact Cloud Catalog

We present a catalog of 1964 isolated, compact neutral hydrogen clouds from the Galactic Arecibo L-Band Feed Array Survey Data Release One (GALFA-HI DR1). The clouds were identified by a custom machine-vision algorithm utilizing Difference of Gaussian kernels to search for clouds smaller than 20'. The clouds have velocities typically between |VLSR| = 20-400 km/s, linewidths of 2.5-35 km/s, and column densities ranging from 1 - 35 x 10^18 cm^-2. The distances to the clouds in this catalog may cover several orders of magnitude, so the masses may range from less than a Solar mass for clouds within the Galactic disc, to greater than 10^4 Solar Masses for HVCs at the tip of the Magellanic Stream. To search for trends, we separate the catalog into five populations based on position, velocity, and linewidth: high velocity clouds (HVCs); galaxy candidates; cold low velocity clouds (LVCs); warm, low positive-velocity clouds in the third Galactic Quadrant; and the remaining warm LVCs. The observed HVCs are found to be associated with previously-identified HVC complexes. We do not observe a large population of isolated clouds at high velocities as some models predict. We see evidence for distinct histories at low velocities in detecting populations of clouds corotating with the Galactic disc and a set of clouds that is not corotating.Comment: 34 Pages, 9 Figures, published in ApJ (2012, ApJ, 758, 44), this version has the corrected fluxes and corresponding flux histogram and masse

Effectiveness of smoking cessation therapies: a systematic review and meta-analysis

BACKGROUND: Smoking remains the leading preventable cause of premature deaths. Several pharmacological interventions now exist to aid smokers in cessation. These include Nicotine Replacement Therapy [NRT], bupropion, and varenicline. We aimed to assess their relative efficacy in smoking cessation by conducting a systematic review and meta-analysis. METHODS: We searched 10 electronic medical databases (inception to Sept. 2006) and bibliographies of published reviews. We selected randomized controlled trials [RCTs] evaluating interventions for smoking cessation at 1 year, through chemical confirmation. Our primary endpoint was smoking cessation at 1 year. Secondary endpoints included short-term smoking cessation (~3 months) and adverse events. We conducted random-effects meta-analysis and meta-regression. We compared treatment effects across interventions using head-to-head trials and when these did not exist, we calculated indirect comparisons. RESULTS: We identified 70 trials of NRT versus control at 1 year, Odds Ratio [OR] 1.71, 95% Confidence Interval [CI], 1.55–1.88, P =< 0.0001). This was consistent when examining all placebo-controlled trials (49 RCTs, OR 1.78, 95% CI, 1.60–1.99), NRT gum (OR 1.60, 95% CI, 1.37–1.86) or patch (OR 1.63, 95% CI, 1.41–1.89). NRT also reduced smoking at 3 months (OR 1.98, 95% CI, 1.77–2.21). Bupropion trials were superior to controls at 1 year (12 RCTs, OR1.56, 95% CI, 1.10–2.21, P = 0.01) and at 3 months (OR 2.13, 95% CI, 1.72–2.64). Two RCTs evaluated the superiority of bupropion versus NRT at 1 year (OR 1.14, 95% CI, 0.20–6.42). Varenicline was superior to placebo at 1 year (4 RCTs, OR 2.96, 95% CI, 2.12–4.12, P =< 0.0001) and also at approximately 3 months (OR 3.75, 95% CI, 2.65–5.30). Three RCTs evaluated the effectiveness of varenicline versus bupropion at 1 year (OR 1.58, 95% CI, 1.22–2.05) and at approximately 3 months (OR 1.61, 95% CI, 1.16–2.21). Using indirect comparisons, varenicline was superior to NRT when compared to placebo controls (OR 1.66, 95% CI 1.17–2.36, P = 0.004) or to all controls at 1 year (OR 1.73, 95% CI 1.22–2.45, P = 0.001). This was also the case for 3-month data. Adverse events were not systematically different across studies. CONCLUSION: NRT, bupropion and varenicline all provide therapeutic effects in assisting with smoking cessation. Direct and indirect comparisons identify a hierarchy of effectiveness

Inhibition of carcinogen induced c-Ha-ras and c-fos proto-oncogenes expression by dietary curcumin

BACKGROUND: We investigated the chemopreventive action of dietary curcumin on 7,12-dimethylbenz(a)anthracene (DMBA)-initiated and 12,0-tetradecanoylphorbol-13-acetate (TPA)-promoted skin tumor formation in Swiss albino mice. Curcumin, a yellow coloring matter isolated from roots of Curcuma longa Linn, is a phenolic compound possessing antioxidant, free radical scavenger, and antiinflammatory properties. It has been shown by previously reported work that TPA-induced skin tumors were inhibited by topical application of curcumin, and curcumin has been shown to inhibit a variety of biological activities of TPA. Topical application of curcumin was reported to inhibit TPA-induced c-fos, c-jun and c-myc gene expression in mouse skin. This paper reports the effects of orally administered curcumin, which was consumed as a dietary component at concentrations of 0.2 % or 1 %, in ad libitum feeding. RESULTS: Animals in which tumors had been initiated with DMBA and promoted with TPA experienced significantly fewer tumors and less tumor volume if they ingested either 0.2% or 1% curcumin diets. Also, the dietary consumption of curcumin resulted in a significantly decreased expression of ras and fos proto-oncogenes in the tumorous skin, as measured by enhanced chemiluminesence Western blotting detection system (Amersham). CONCLUSIONS: Whereas earlier work demonstrated that topical application of curcumin to mouse skin inhibited TPA-induced expression of c-fos, c-jun and c-myc oncogenes, our results are the first to show that orally consumed curcumin significantly inhibited DMBA- and TPA-induced ras and fos gene expression in mouse skin

Usage Patterns of Stop Smoking Medications in Australia, Canada, the United Kingdom, and the United States: Findings from the 2006–2008 International Tobacco Control (ITC) Four Country Survey

Varenicline is a new prescription stop smoking medication (SSM) that has been available in the United States since August 1, 2006, in the United Kingdom and other European Union countries since December 5, 2006, in Canada since April 12, 2007, and in Australia since January 1, 2008. There are few population-based studies that have examined use rates of varenicline and other stop smoking medications. We report data from the ITC Four Country survey conducted with smokers in the US, UK, Canada, and Australia who reported an attempt to quit smoking in past year in the 2006 survey (n = 4,022 participants), 2007 (n = 3,790 participants), and 2008 surveys (n = 2,735 participants) Respondents reported use of various stop smoking medications to quit smoking at each survey wave, along with demographic and smoker characteristics. The self-reported use of any stop smoking medication has increased significantly over the 3 year period in all 4 countries, with the sharpest increase occurring in the United States. Varenicline has become the second most used stop smoking medication, behind NRT, in all 4 countries since being introduced. Between 2006 and 2008, varenicline use rates increased from 0.4% to 21.7% in the US, 0.0% to 14.8% in Canada, 0.0% to 14.5% in Australia, and 0.0% to 4.4% in the UK. In contrast, use of NRT and bupropion remained constant in each country. Males and non-whites were significantly less likely to report using any SSM, while more educated smokers were significantly more likely to use any SSM, including varenicline. Our findings suggest that the introduction of varenicline led to an increase in the number of smokers who used evidence-based treatment during their quit attempts, rather than simply gaining market share at the expense of other medications. From a public health perspective, messages regarding increased success rates among medication users and the relative safety of stop smoking medications should be disseminated widely so as to reach all smokers of all socioeconomic classifications equally

Rapid reduction versus abrupt quitting for smokers who want to stop soon: a randomised controlled non-inferiority trial

Background: The standard way to stop smoking is to stop abruptly on a quit day with no prior reduction in consumption of cigarettes. Many smokers feel that reduction is natural and if reduction programmes were offered, many more might take up treatment. Few trials of reduction versus abrupt cessation have been completed. Most are small, do not use pharmacotherapy, and do not meet the standards necessary to obtain a marketing authorisation for a pharmacotherapy.\ud Design/Methods: We will conduct a non-inferiority andomised trial of rapid reduction versus standard abrupt cessation among smokers who want to stop smoking. In the reduction arm,participants will be advised to reduce smoking consumption by half in the first week and to 25% of baseline in the second, leading up to a quit day at which participants will stop smoking completely.This will be assisted by nicotine patches and an acute form of nicotine replacement therapy. In the abrupt arm participants will use nicotine patches only, whilst smoking as normal, for two weeks prior to a quit day, at which they will also stop smoking completely. Smokers in either arm will have standard withdrawal orientated behavioural support programme with a combination of nicotine patches and acute nicotine replacement therapy post-cessation.\ud Outcomes/Follow-up: The primary outcome of interest will be prolonged abstinence from smoking, with secondary trial outcomes of point prevalence, urges to smoke and withdrawal\ud symptoms. Follow up will take place at 4 weeks, 8 weeks and 6 months post-quit day

Fostering Continuous Innovation with Engaging IT-Assisted Transparent Information Sharing : A Case Study

The paper received the Honorary Mention – Best Paper Award Nominee.Peer reviewe